Sage Therapeutics' SAGE-718 Gets FDA ODD; Bullish View On TeraWulf
- October 18th, 2023
- 572 views
Shares of Sage Therapeutics, Inc. (Nasdaq: SAGE), a leading biopharmaceutical company specializing in neurological and neuropsychiatric disorders, surged over 5% in pre-market trading after the company said that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718, a potential treatment for Huntington’s disease (HD).
HD, a rare and progressive neurodegenerative condition, impacts an estimated 40,000 U.S. adults annually, with severe cognitive effects.
$SAGE was trading at $21.05 in pre-market, up $1.41 (7.18%).
In other news, Stifel has initiated coverage on TeraWulf Inc. (Nasdaq: WULF), an infrastructure-focused bitcoin mining company, with a Buy rating and set a price target of $3.
Based on Tuesday's closing price of $1.24, the assigned price target implies a potential upside of $1.76 or approximately 141.94% for $WULF, according to the investment banking firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025Earnings Preview: Credo Technology, MongoDB, and Hafnia in Focus
November 30th, 2025
Member Login